Stay updated with breaking news from Acrx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com upgraded shares of AcelRx Pharmaceuticals (NASDAQ:ACRX – Get Rating) from a sell rating to a hold rating in a research report report published on Friday. AcelRx Pharmaceuticals Price Performance ACRX stock opened at $0.64 on Friday. The company’s 50-day moving average is $1.21 and its 200-day moving average is $2.72. The stock has a […]
AcelRx Pharmaceuticals (NASDAQ:ACRX – Get Rating) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Friday. AcelRx Pharmaceuticals Stock Down 0.8 % Shares of NASDAQ ACRX traded down $0.01 during midday trading on Friday, hitting $0.62. The stock had a […]
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX – Get Rating) – Investment analysts at Cantor Fitzgerald cut their FY2023 earnings estimates for AcelRx Pharmaceuticals in a research report issued on Monday, April 3rd. Cantor Fitzgerald analyst B. Folkes now expects that the specialty pharmaceutical company will post earnings per share of ($2.41) for the year, down from their […]
AcelRx Pharmaceuticals (NASDAQ: ACRX) recently received a number of ratings updates from brokerages and research firms: 5/21/2022 – AcelRx Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock. 5/19/2022 – AcelRx Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. […]
StockNews.com began coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX – Get Rating) in a research report issued on Thursday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock. A number of other brokerages have also weighed in on ACRX. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of AcelRx Pharmaceuticals in a […]